Evidence map›Paper›PMID 28038451›Full record

ArticleOncotarget2017

Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.

Kevin J Tam, Kush Dalal, Michael Hsing, Chi Wing Cheng, Shahram Khosravi, Parvin Yenki, Charan Tse, James W Peacock, Aishwariya Sharma, Yan Ting Chiang and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.International journal of molecular sciences · 2019
    Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Kevin J TamVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Kush DalalVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Michael HsingVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Chi Wing ChengVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Shahram KhosraviVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Parvin YenkiVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Charan TseVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
James W PeacockVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Aishwariya SharmaVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Yan Ting ChiangVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Yuzhuo WangVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Artem CherkasovVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Paul S RennieVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Martin E GleaveVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Christopher J OngVancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Vancouver General Hospital · CAUniversity of British Columbia · CA

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
NCI NIH HHS P50 CA097186
6 · The paper itself

Abstract

The androgen receptor (AR) is a member of the nuclear receptor superfamily of transcription factors and is central to prostate cancer (PCa) progression. Ligand-activated AR engages androgen response elements (AREs) at androgen-responsive genes to drive the expression of gene batteries involved in cell proliferation and cell fate. Understanding the transcriptional targets of the AR has become critical in apprehending the mechanisms driving treatment-resistant stages of PCa. Although AR transcription regulation has been extensively studied, the signaling networks downstream of AR are incompletely described. Semaphorin 3C (SEMA3C) is a secreted signaling protein with roles in nervous system and cardiac development but can also drive cellular growth and invasive characteristics in multiple cancers including PCa. Despite numerous findings that implicate SEMA3C in cancer progression, regulatory mechanisms governing its expression remain largely unknown. Here we identify and characterize an androgen response element within the SEMA3C locus. Using the AR-positive LNCaP PCa cell line, we show that SEMA3C expression is driven by AR through this element and that AR-mediated expression of SEMA3C is dependent on the transcription factor GATA2. SEMA3C has been shown to promote cellular growth in certain cell types so implicit to our findings is the discovery of direct regulation of a growth factor by AR. We also show that FOXA1 is a negative regulator of SEMA3C. These findings identify SEMA3C as a novel target of AR, GATA2, and FOXA1 and expand our understanding of semaphorin signaling and cancer biology.

Indexed as

Transcription, GeneticAntineoplastic AgentsCell Line, TumorCell ProliferationDose-Response Relationship, DrugGATA2 Transcription FactorGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-alphaHumansMaleProstatic NeoplasmsReceptors, AndrogenResponse ElementsSemaphorinsSignal TransductionTestosterone CongenersAntineoplastic AgentsAR protein, humanFOXA1 protein, humanGATA2 protein, humanGATA2 Transcription FactorHepatocyte Nuclear Factor 3-alphaReceptors, AndrogenSema3C protein, humanSemaphorinsTestosterone Congenersandrogen receptorFOXA1GATA2POU2F1SEMA3C

Identifiers

PMID28038451
PMCPMC5354758
OpenAlexW2566616587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.